Competitor Landscape: Idiopathic Pulmonary Fibrosis (IPF)
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
Executive Summary: Contains analysis of key market events that have occurred during the previous month and which have impacted Sociable Pharma’s view of the disease landscape
Landscape Updates: ‘Order of Entry’ analysis, detailing timeline forecasts for each drug in Phase II development or higher; Timeline forecasts for each approved product’s lifecycle management initiatives; ‘Market Entry’ & ‘Direction of Travel’ positioning analysis for pipeline & currently approved therapies
Pipeline Landscape: An overview of pipeline candidates, containing snapshots of current development status; Expected drug-specific events & milestones until YE 2019
Approved Product Landscape: An overview of pipeline candidates, containing snapshots of current development status; Expected drug-specific events & milestones until YE 2019
Scope
The briefing is based on Sociable Pharma’s analysis of clinical trial data from company announcements (press releases, earnings calls) and clinical trial databases (clinicaltrials.gov)
Sociable Pharma applies disease & drug specific assumptions in order to forecast US & EU approvals for drugs in Phase II development, or higher – these are outlined in the report Appendix
Forecasts are presented in pipeline forecast figures & detailed tables
‘Market Entry’ & ‘Direction of Travel’ positioning analysis for pipeline & currently approved therapies is also provided
Key Highlights
Development of PBI-4050 is expected to be delayed, due to Prometic’s need for financing, potentially losing its first mover position vs. FibroGen & Galapagos, which have already announced the timeline for their respective Phase III trials
FibroGen’s pamrevlumab is expected to be the second novel candidate to achieve approval in IPF (pending successful Phase III trials), and its approval could be accelerated due to the fast track designation in the US
Promedior’s PRM-151 is expected to be the third novel therapy to be approved in IPF, however, Promedior did not provide a clear timeline for Phase III trial initiation, suggesting a potential delay in its development
Reasons to Buy
Provides details on forecast US & EU approvals for pipeline drugs in Phase II development or higher
Includes potential positioning strategies that companies may adopt for their novel assets once they are approved & launched in the market
Reviews ongoing lifecycle management strategies for existing players in the market
A detailed methodology allows you to understand the forecast assumptions made, enabling cross comparison with your own internal forecasts
Afferent Pharmaceuticals/Merck
Analyn
Ark Biosciences
Biogen
BMS
Boehringer Ingelheim
Bridge Biotherapeutics
Celgene
FibroGen
Galapagos
Galecto Biotech
Genkyotex
Global Blood Therapeutics
GSK
Guangdong Zhongsheng Pharma
HEC Pharm
Kadmon Corporation
MediciNova
Metagone Biotech
Moerae Matrix
Nitto Biopharma
Novartis
Patara Pharma
Pharmaxis
Promedior
Prometic
Reviva Pharma
Roche
Roivant Sciences
Samumed
Sanofi
Synairgen
United therapeutics
Vicore Pharma
X-Rx
ZAI Lab
Table of Contents
Frequently asked questions
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.